{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T10:53:21Z","timestamp":1794135201985,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2025.05.023","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:07:30Z","timestamp":1748545650000},"page":"471-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-1006","authenticated-orcid":false,"given":"Allen","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sheidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Intorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"McKeown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-7311","authenticated-orcid":false,"given":"Ursula M.","family":"Schmidt-Erfurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata P.","family":"Sarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.05.023_bib0001","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ajo.2025.05.023_bib0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.023_bib0003","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/2474126419859454","article-title":"Percentage of foveal vs total macular geographic atrophy as a predictor of visual acuity in age-related macular degeneration","volume":"3","author":"Bagheri","year":"2019","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.ajo.2025.05.023_bib0004","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.oret.2022.05.030","article-title":"The effect of pegcetacoplan treatment on photoreceptor maintenance in geographic atrophy monitored by artificial intelligence-based OCT analysis","volume":"6","author":"Riedl","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.05.023_bib0005","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ophtha.2013.01.049","article-title":"Characteristics of incident geographic atrophy in the complications of age-related macular degeneration prevention trial","volume":"120","author":"Brader","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.023_bib0006","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.oret.2020.01.019","article-title":"Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.05.023_bib0007","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ajo.2017.03.031","article-title":"Geographic atrophy and foveal-sparing changes related to visual acuity in patients with dry age-related macular degeneration over time","volume":"179","author":"Sayegh","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.023_bib0008","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.oret.2020.11.003","article-title":"Relationship of topographic distribution of geographic atrophy to visual acuity in nonexudative age-related macular degeneration","volume":"5","author":"Shen","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.05.023_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19413-z","article-title":"Prediction of visual function from automatically quantified optical coherence tomography biomarkers in patients with geographic atrophy using machine learning","volume":"12","author":"Balaskas","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajo.2025.05.023_bib0010","doi-asserted-by":"crossref","first-page":"Bio61","DOI":"10.1167\/iovs.16-21210","article-title":"Combined fundus autofluorescence and near infrared reflectance as prognostic biomarkers for visual acuity in foveal-sparing geographic atrophy","volume":"58","author":"Lindner","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.05.023_bib0011","series-title":"Head and Neck, Eye Fovea","author":"Rehman","year":"2024"},{"key":"10.1016\/j.ajo.2025.05.023_bib0012","unstructured":"Izervay [package insert]. Northbrook, IL: Astellas Pharma, 2025."},{"key":"10.1016\/j.ajo.2025.05.023_bib0013","unstructured":"Syfovre [package insert]. Waltham, MA: Apellis Pharmaceuticals, Inc., 2024."},{"key":"10.1016\/j.ajo.2025.05.023_bib0014","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.05.023_bib0015","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2025.05.023_bib0016","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(23)01583-0","article-title":"Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial","volume":"402","author":"Khanani","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2025.05.023_bib0017","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","article-title":"Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study)","volume":"123","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.023_bib0018","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1167\/iovs.07-1132","article-title":"Report from the NEI\/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium","volume":"49","author":"Csaky","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.05.023_bib0019","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ajo.2024.02.021","article-title":"Drug approval for the treatment of geographic atrophy: how we got here and where we need to go","volume":"263","author":"Csaky","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.05.023_bib0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ophtha.2024.08.017","article-title":"Disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT","volume":"132","author":"Schmidt-Erfurth","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.023_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100372","article-title":"Magnitude of visual acuity change with ETDRS versus Snellen testing in clinical trials: implications for clinic-based outcomes","volume":"4","author":"Salabati","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.ajo.2025.05.023_bib0022","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","article-title":"Visual acuity as an outcome measure in clinical trials of retinal diseases","volume":"114","author":"Beck","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.05.023_bib0023","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1167\/iovs.08-3225","article-title":"Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials","volume":"50","author":"Su\u00f1er","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.05.023_bib0024","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.oret.2022.08.003","article-title":"Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning","volume":"7","author":"Vogl","year":"2023","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ajo.2025.05.023_bib0025","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ajo.2025.05.023_bib0026","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12874-016-0170-y","article-title":"Best practice for analysis of shared clinical trial data","volume":"16","author":"Hollis","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ajo.2025.05.023_bib0027","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s41433-022-01948-0","article-title":"When to believe a subgroup analysis: revisiting the 11 criteria","volume":"36","author":"Farrokhyar","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2025.05.023_bib0028","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/PPA.S386662","article-title":"Towards a therapy for geographic atrophy: a patient's experience","volume":"17","author":"Enoch","year":"2023","journal-title":"Patient Prefer Adherence"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425002600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425002600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T13:20:51Z","timestamp":1754918451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425002600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"alternative-id":["S0002939425002600"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.05.023","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual Acuity and Quality of Life Outcomes With Pegcetacoplan Treatment: A Post Hoc Analysis From the OAKS and DERBY Trials","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}